A new treatment against Clostridium difficile

被引：0
|
作者：
Erb, William [1 ]
Zhu, Jieping [2 ]
机构：
[1] Univ Bristol, Sch Chem, Bristol BS8 1TH, Avon, England
[2] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, EPFL SB ISIC LSPN, CH-1015 Lausanne, Switzerland
来源：
ACTUALITE CHIMIQUE | 2012年 / 360期
关键词：
Clostridium difficile; infections; diarrheas; COD; fidaxomicin; tiacumicin; antibiotics therapy; ARMENIACA SUBSP NOV; IN-VITRO ACTIVITIES; BACTERIAL TRANSCRIPTION; NATURAL-PRODUCTS; RNA-POLYMERASE; LIPIARMYCIN; ANTIBIOTICS; INFECTION; VANCOMYCIN; DIARRHEA;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
A new treatment against Clostridium difficile Clostridium difficile associated diarrheas (ODD) are one of the major secondary infections encountered in patients under antibiotics therapy. In spite of inherent drawbacks associated with vancomycin and metronidazole, these two broad-spectrum antibiotics are currently prescribed for the treatment of ODD. The natural molecule known as tiacumicin B or fidaxomicin has recently been approved by FDA to treat Clostridium difficile infections. This article briefly recalls the essential of antibiotics, of Clostridium difficile and discusses the isolation, biosynthesis, mode of action and structure-activity relationship of tiacumicin B.
引用
收藏
页码：83 / 89
页数：7
相关论文
共 50 条
  • [11] Synthesis and antibacterial activity against Clostridium difficile of novel demethylvancomycin derivatives
    Zhang, Si-Ji
    Yang, Qing
    Xu, Liang
    Chang, Jun
    Sun, Xun
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (15) : 4942 - 4945
  • [12] Fidaxomicin: a new option for the treatment of Clostridium difficile infection
    Johnson, Alan P.
    Wilcox, Mark H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (12) : 2788 - 2792
  • [13] Treatment of Clostridium difficile infections: Old and new approaches
    Barbut, F.
    Meynard, J. -L.
    Eckert, C.
    JOURNAL DES ANTI-INFECTIEUX, 2011, 13 (02) : 74 - 86
  • [14] Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic
    Sears, Pamela
    Ichikawa, Yoshi
    Ruiz, Nancy
    Gorbach, Sherwood
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012, 2013, 1291 : 33 - 41
  • [15] Prevention and treatment of Clostridium difficile associated diarrhea by reconstitution of the microbiota
    Eliakim-Raz, Noa
    Bishara, Jihad
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (06) : 1453 - 1456
  • [16] MONOCLONAL ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE INFECTION IN THE PIPELINE
    Lo Vecchio, A.
    Liguoro, I.
    Scotto, R.
    DRUGS OF THE FUTURE, 2014, 39 (10) : 693 - 700
  • [17] New Guidelines and Data to Clostridium difficile Whats New?
    Luebbert, Christoph
    Lippmann, Norman
    von Braun, Amrei
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2018, 143 (11) : 787 - 792
  • [18] Epidemiology, diagnosis and treatment of Clostridium difficile infection
    Bassetti, Matteo
    Villa, Giovanni
    Pecori, Davide
    Arzese, Alessandra
    Wilcox, Mark
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (12) : 1405 - 1423
  • [19] A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
    Endres, Bradley
    Basseres, Eugenie
    Rashid, Tasnuva
    Chang, Long
    Alam, M. Jahangir
    Garey, Kevin W.
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2017, (123):
  • [20] The Use of Fidaxomicin for Treatment of Relapsed Clostridium difficile Infections in Patients with Cancer
    Esmaily-Fard, Amin
    Tverdek, Frank P.
    Crowther, David M.
    Ghantoji, Shashank S.
    Adachi, Javier A.
    Chemaly, Roy F.
    PHARMACOTHERAPY, 2014, 34 (11): : 1220 - 1225
12345